| News

Roche testing for coronavirus and flu simultaneously

04.09.2020

The U.S. Food and Drug Administration has given the Basel-based life sciences company Roche authorization to use a test that simultaneously tests for the coronavirus and flu infections. Roche is also launching a rapid antigen test for coronavirus.

Roche has developed a testing process for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in patients. This can be done with a single sample. According to a press release, the U.S. Food and Drug Administration (FDA) has authorized Roche to use this test in laboratories with the relevant certification. It has done so through Emergency Use Authorization, which means final authorization and approval have not yet been granted.

“With the approaching flu season, this new test is particularly important as SARS-CoV-2 and influenza infections can hardly be differentiated by symptoms alone. Now, with a single test, healthcare professionals can confidently provide the right diagnosis and most effective treatment plan for their patients,” said Thomas Schinecker, CEO of Roche Diagnostics.

The test is carried out with Roche’s widely-available, fully-automated cobas 6800/8800 systems, which provide up to 96 results in just three hours. Roche is thereby expanding its portfolio to include solutions for the fight against COVID-19. As recently as 1 September, a rapid antigen test for coronavirus had been announced. It will be launched at the end of this month. Roche intends to apply to the FDA for Emergency Use Authorization for this test as well.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
1 2 3 48

Do you have a question? We'd like to hear from you.